{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-017185","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.534991+00:00","generated_at":"2026-05-21T05:20:55.128912+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reviva Q1 2025 net loss $6.4M; cash $5.3M; OLE trial complete with 446 patients","bullets":["Net loss $6.4M ($0.13/sh) vs $7.4M ($0.25/sh) in Q1 2024; cash & equivalents $5.3M as of Mar 31, 2025 down from $13.5M at Dec 31, 2024.","Long-term OLE trial of brilaroxazine completed: 446 participants, 156 completed 12 months, 301 completed 6 months.","Full OLE data (safety, efficacy, biomarkers) expected Q2 2025; registrational Phase 3 RECOVER-2 initiation expected mid-2025 subject to financing.","NDA submission for brilaroxazine in schizophrenia targeted for Q4 2026; IND for psoriasis liposomal-gel formulation expected later in 2025.","Company to present late-breaking poster on RECOVER 12-month OLE data at ASCP meeting on May 28, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-017185","json":"https://secwatch.observer/filing/0001437749-25-017185.json","markdown":"https://secwatch.observer/filing/0001437749-25-017185.md","text":"https://secwatch.observer/filing/0001437749-25-017185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/0001437749-25-017185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/rvph20250507_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:20:55.128912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}